Open Access
Review Article
Table 2
Sensitivity, Specificity, PPV and NPV of anti-Toxoplasma IgG commercial assays included in the study.
| Assay | Sensitivity mean % (range) | Specificity mean % (range) | PPV mean % (range) | NPV mean % (range) | Comments |
|---|---|---|---|---|---|
| Access Toxo IgG II® | 89.7 | 100 | 100 | 92.8 | |
| Low IgG: 13.4 | Low IgG: 99.6 | ||||
| Advia Centaur® | 100 | 100 | 100 | 100 | Single study |
| Low IgG: 51.1 | |||||
| Architect Toxo IgG® | 90.7 (80.8–99.6) | 99.8 (99.5–100) | 99.7 (99.1–100) | 97.3 (94.6–99.5) | For low IgG, one study did not provide crude results [13] |
| Low IgG: 30.5 (12–43.9) | Low IgG: 100 | ||||
| Axsym Toxo IgG® | 96.1 (90.2–99.6) | 99.7 (99.5–100) | 99.7 (99.4–100) | 97.2 (93.1–99.5) | |
| BioPlex 2200 ToRCH IgG/IgM® | 97.8 | 91.3 | 98.5 | 87.5 | Single study |
| Elecsys Toxo IgG® | 98.6 (97.5–100) | 99.6 (98.7–100) | 99.2 (98.3–100) | 99.4 (98.7–100) | 100% concordance with DT for sera with interfering diseases |
| Low IgG: 88.6 (73.2–95.6) | Low IgG: 99.6 (99.3–100) | ||||
| Immulite 2000 anti-Toxoplasma IgG® | 93.5 (87.9–99) | 99.8 (99.6–100) | 99.4 | 92.7 | |
| Liaison Toxo IgG II® | 94.8 (93.8–95.8) | 99.5 (na) | 98.2 (96.8–99.5) | 97.4 (95.7–99.1) | One study merged results obtained with low and standard IgG titers (58.9% sensitivity) |
| Low IgG: 25.5 (6.7–58.9) | Low IgG: 100 | ||||
| Platelia Toxo IgG® | 96.4 (95.6–97.2) | 99.4 (98.7–100) | 98.4 (96.7–100) | 97.7 (97.1–98.3) | In one study, only 29/56 discrepant EIA were confirmed by DT |
| Low IgG: 47.6 (32.9–62.2) | Low IgG: 100 | ||||
| TGS TA Toxo IgG/IDS-iSYS® | 97 | 97 | nd | nd | |
| Low IgG: 46.3 | Low IgG: 96.7 | Low IgG: 86.4 | Low IgG: 79.8 | ||
| Vidas Toxo IgG® | 95.5 (91.4–100) | 99.8 (99.5–100) | 99.1 (96.8–100) | 97.7 (93.9–99.5) | |
| Low IgG: 44.2 (12.2–63.3) | Low IgG: 99.7 (99–100) | ||||
| Vitros ECiQ Toxoplasma IgG® | 93.4 | 100 | nd | nd | Single study, no separate analysis of IgG et IgM results |
| Pastorex Toxo® | 98.8 | 98.8 | 98.8 | 98.8 | Single study, 6.5% false-positive with interfering diseases, sensitivity 97.3% and 100% in acute and chronic toxoplasmosis, respectively |
| Low IgG: 51.5 | |||||
| Toxocell® | 96.8 | 97.6 | 97.6 | 96.8 | Single study, 11% false-positive results with interfering diseases, Sensitivity 97.3% and 100% in acute and chronic toxoplasmosis, respectively |
| Low IgG: 66.7 | |||||
| Toxo HAI® | 100 | 99.2 | 99.2 | 100 | Single study, 4.3% false-positive results with interfering diseases, Sensitivity 97.3% and 100% in acute and chronic toxoplasmosis, respectively |
| Low IgG: 97 | |||||
| Toxolatex® | 93.7 | 97.1 | 97.1 | 93.7 | Single study, 11% false-positive results with interfering diseases, Sensitivity 94.6% and 100% in acute and chronic toxoplasmosis, respectively |
| Low IgG: 51.5 | |||||
| OnSite Toxo IgG/IgM Combo Rapid Test® | 100 | 98 | 98.8 | 100 | Single study |
| Detects both specific IgG and IgM | |||||
| Toxo IgG/IgM Rapid Test ® Biopanda | 100 | 96 | 98.3 | 100 | Single study |
| Detects both specific IgG and IgM | |||||
| Toxoplasma ICT IgG/IgM® LDBio | 100 | 99.1 (98.6–100) | 97.6 (95.8–99.4) | 100 | Detects both specific IgG and IgM, 100% sensitivity in acute infections, 100% concordance with WB Toxo IgGII |
| WB Toxo IgGII® | Low IgG: 99.2 | 100 | 100 | 99.2 | Single study, 99.4% NPV, 100% concordance with DT for equivocal sera and interfering diseases |
PPV: positive predictive value; NPV: negative positive value; DT: dye-test; na: not applicable; nd: not determined.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.